English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Anti-muscle-specific kinase (MuSK) antibody positive generalized myasthenia gravis (MuSK-MG) is an autoimmune disease, in which deterioration of myasthenic symptoms may occur by cholinesterase inhibitor (ChE-I) treatment. Salbutamol, a sympathetic β2 receptor agonist, was an effective therapeutic drug in congenital myasthenic syndrome patients with MuSK gene abnormalities and in MuSK-MG animal model. Salbutamol was attempted to treat a female MuSK-MG patient who did not respond to ChE-I. Any acute benefit of salbutamol was not observed but her myasthenic symptoms gradually improved over a year without adversive effects. Salbutamol may be a therapeutic drug to alleviate myasthenic symptoms in MuSK-MG patients.

international journal of neurology and neurotherapy

A Female Patient with Anti-Muscle-Specific Kinase Antibody Positive Generalized Myasthenia Gravis Responded to Salbutamol but not Pyridostigmine: A Case Report